Table I.

Other cases of immunotherapy-induced sclerotic skin disease

Drug(s)	Target	Patient sex, age, and indication	irAE	Time from drug onset to iRAE	Treatment of SLS and result	SLS treatment response outcome
Pembrolizumab Ipilimumab Nivolumab	PD-1, CTLA-4	61 M, Melanoma	Generalized morphea associated with eosinophilia4	10 mos (from combined immunotherapy onset)	Dexamethasone pulse dosing and clobetasone propionate	Improvement but not resolution
Nivolumab	PD-1	70 (s) M, Melanoma	SLS with no system symptoms5	54 wks	Prednisolone, 20 mg/d (0.3 mg/kg)	Resolution after 9-mo prednisone taper
Nivolumab	PD-1	61 M, Oligometastatic renal cell carcinoma	Scleroderma-like skin changes6	32 wks	Prednisone, mycophenolate mofetil	Improved; flared after prednisone taper requiring mycophenolate mofetil

irAE, Immune-related adverse event; SLS, scleroderma-like syndrome.